Unravelling The Complexity Of Tumor Microenvironment With High-Dimensional IHC Analysis Platform

27th August 2021, 4pm – 5pm SGT

A comprehensive understanding of the tumor microenvironment, including stromal composition, cell-cell and cell-matrix interactions, abnormal physiology, as well as cellular characteristics of heterogenous tumors is the key to elucidating cancer complexities. Understanding the cellular, molecular, and biochemical interactions of tumors within their microenvironment is essential to improving cancer diagnosis and treatment.

With multiplexing IHC (mlHC) technologies and high-content pathological analysis platform, scientists can simultaneously detect multiple markers on a single tissue section and the comprehensive study of cell composition, cellular functional and cell-cell interactions. mlHC provides high-throughput multiplex staining and standardized quantitative analysis for highly reproducible, efficient and cost-effective tissue studies. This technique has immediate potential for translational research and clinical practice, particularly in the era of tumor microenvironment study and cancer immunotherapy.


Speaker's Biographies

By Dr Edward, Li
International Strategic Marketing Manager

Review employee support systems and work policies to ensure they are forward thinking

Organizations should constantly improve their talent acquisition and retention framework, review workflows to improve processes, build up financial standing with external stakeholders and adopt automation technology to reduce burden where possible, believes Ng Boon Thiam, Group CEO of Biomed Global.

Ng Boon Thiam is the Group CEO of Biomed Global – one of the most respected channels in the biomedical and life sciences industry in Malaysia and Singapore. Recognizing the need to improve the standards of healthcare in Malaysia, he started Biomarketing Services (now known as Biomed Global) in 1994 together with his business partner, Chen Keng Hoong. Over the years, Biomed Global has performed strongly in Malaysia and Singapore and has expanded regionally to a number of ASEAN countries. Now, the company has grown to be a significant total solution provider for Clinical Diagnostics and Life Science.

In an exclusive interaction with us, Ng Boon Thiam shares with us how Biomed Global is navigating the second wave and how it is bolstering employee support systems and work policies to support the workforce.

The toughest time is looming as companies have to ensure business continuity and productive output while supporting their workers amid the resurgence of the virus. How is Biomed Global ensuring that?

Biomed Global is in the Clinical Diagnostics Industry which is a critical piece of the country’s healthcare infrastructure. As such, the whole team has been working extremely hard to ensure continuous supply lines, installations, commissioning, trainings and subsequent support to keep the operation going. This pandemic has further empowered our team members to live to our mission of raising the quality of healthcare standards and live to our tag line of Enriching Partners, Enriching Lives.

Biomed formed a Business Continuity Plan (BCP) committee right before the country implemented (Movement Control Order) MCO 1.0 to ensure compliance to the necessary SOPs and take extra care of our team’s wellbeing. The company has granted MCO meal allowances under special circumstances, maintained annual increments and additional remuneration to recognize the various team members who had to take on risks to carry out their tasks professionally. The various events such as making an extra effort for a shipment, special delivery for installation, and training and repairs were communicated and highlighted to all team members so that the efforts are well recognized. The overall morale during this pandemic remains high.

How should organizations rethink talent management amid all this uncertainty? What is Biomed Global’s focus here?

First and foremost, organizations need to be filled with talent that is in sync with the company’s Mission and Values. Talent that is agile and adaptable in this new norm, with a skill set in digitalization, a strong mindset to face any eventuality is greatly valued now. Biomed operates on a performance-based talent strategy, as such our focus is on retaining our highest performing talents and developing our talents to be high-achievers.

How should organizations level up their employee support systems and work policies? What has Biomed Global done in this regard?

“Organizations should constantly improve their talent acquisition and retention framework, review workflows to improve processes, build up financial standing with external stakeholders and adopt automation technology to reduce burden where possible.”

Biomed has since recruited experienced and strategic team members in Talent Management, Finance, and Supply Chain to support these initiatives. Biomed also constantly reviews our employee support systems and work policies to ensure they are forward-thinking and in line with the best in the industry, if not better.

How are you planning for the future amid predictions of phase three of the virus?

Biomed plans to ensure all team members are protected against COVID-19 by procuring the vaccine for our own workforce if the right vaccine is available commercially. Biomed is also investing to move the remainder of our internal operations onto a cloud-based environment. We have also invested in mobile devices to ensure working from home is possible. As our business is a critical piece of the healthcare infrastructure, we do not expect phase three to have a drastic effect on our business. However, some of our growth plans will be delayed due to uncertainty.

What is the strategy and focus for the leadership to tackle challenges posed by the continuing waves of the virus? Could you shed light on the contingency plan for 2021 and Biomed’s industry outlook for FY 2021-2022?

Biomed is fortunate to be in an essential industry during the COVID-19 pandemic and involved in COVID-19 supplies. Biomed’s leadership will continue to ensure everyone’s safety, to ensure the team can continue to operate without interruption. Biomed will continue to engage with team members regularly via monthly operation meetings, and quarterly town halls.

On the business front, we plan to continue our growth initiatives as well, identify products that will complement our current product portfolio. On COVID-19, Biomed has a total solution platform on COVID-19 diagnosis and will focus on possible automation. Post-vaccination stage, Biomed will very much be focused on immunity monitoring and R&D-related supplies for COVID-19. Biomed is optimistic and the outlook for FY 21-22 will continue to be strong for the group.

Shweta Modgil

A New Platform Technology for Multiplexed Protein Analysis

13th Nov 2020 (Friday), 3pm – 4pm (SGT)

Free Admission



AYOXXA is an NUS spin-off Biotech company. It has developed a novel platform technology that builds on the simple idea to immobilize beads coated with different highly specific antibodies onto a solid-surface array. Detection signals are easily read and mapped by fluorescence microscopy. This setup translates to highly sensitive, precise and accurate multiplexed protein quantification from minute sample volumes as low as 3μl. Its growing portfolio of protein detection panels is supporting research scientists to gain new insights in basic and translational research fields like Ophthalmology, Immuno-Oncology and various others.

If you would like to register your attendance, do scan this QR code or sign up via this link -> https://bit.ly/3ndaNpo

Share this article

Speaker's Biographies

By Dr. Bernd Willems
Scientist and Business Development Manager

Dr. Bernd Willems works with AYOXXA as Scientist and Business Development Manager. Bernd got his PhD from the Department of Biological Sciences at the National University of Singapore.

He then returned to Germany and started his corporate career with a large hospital consortium where he coordinated the Clinical Research arm. Subsequently, he spent three years with QIAGEN as Global Product Manager. In 2017, he joined AYOXXA to represent the company in Singapore.

High Throughput & Automation on Nucleic Acid Purification

26th November 2020, 4pm SGT
Free Admission


For more than 20 years MACHEREY-NAGEL develops & produces a large portfolio of purification technologies and formats to meet your everyday needs. During this time, we gained a lot of experience and created a large knowledge data base to resort to.

Kits for all applications are available for both manual and automated use on common laboratory robotic platforms. Automating nucleic acid purification can reduce errors and save plenty of manual, repetitive work. MN has extensive experience with many well-known automation platforms like Hamilton, epMotions, Tecan & KingFisher platforms.

In this webinar we would like to show you the advantages of silica-based and magnetic bead based extraction kits for certain automated applications and how you can automate your nucleic acid purification workflow.

If you would like to register your attendance, do scan this QR code or sign up via this link -> https://bit.ly/35COnHi

We look forward to having you join us!

Share this article

Speaker's Biographies

By Dr. Ansgar Flammersfeld
Technical Support Specialist

Joined MACHEREY-NAGEL at the beginning of 2020 as a technical support specialist for the MN Bioanalysis products and supports customers with main focus on APAC countries.

Studied molecular & applied biotechnology with a special focus on molecular genetics & recombinant protein expression at the RWTH Aachen (Germany), Fraunhofer Center for Molecular Biotechnology (USA) and at Bayer CropScience (Germany).

Attained his PhD at the RWTH, Aachen, focusing on understanding the molecular mechanisms of the human malarial parasite Plasmodium falciparum.

Challenges of cfDNA, DNA, RNA Isolation from FFPE and Other Clinical Samples

19th November 2020, 4pm SGT
Free Admission


Reliable clinical sample analysis plays an essential role in human healthcare or disease control & strongly depends on products of high performance & quality. Clinical sample isolation & subsequent processing is demanding on several levels. Probably the most challenging aspect of handling clinical samples is their sheer diversity: blood & various other body fluids, stool samples, & formaldehyde-fixed, paraffin-embedded (FFPE) microscopy slides, all fall under the category of clinical samples.

Furthermore, the nucleic acid of interest can originate from both humans as well as their various parasites including, but not limited to viruses, bacteria, & protozoans. With our expertise in DNA & RNA purification from a wide variety of samples as well as extensive experience in making clinical products, MACHEREY-NAGEL is the partner of choice for your clinical project.

Join Dr. Thomas Winkelmüller in this webinar, where you will learn more about the solutions that MN offers to isolate high quality nucleic acids from clinical samples, ensuring robust results with a high degree of reliability.

If you would like to register your attendance, do scan this QR code or sign up via this link -> https://bit.ly/3ox72Na

We look forward to having you join us!

Share this article

Speaker's Biographies

By Dr. Thomas Winkelmüller
International Sales Manager

Joined MACHEREY-NAGEL 2018 as technical support specialist. Since 2020, he is an international sales manager that manages the international sales for the MN Bioanalysis portfolio in parts of Europe and SouthEast Asia.

He studied biology with a focus on plant-microbe interactions and molecular plant biology at the RWTH Aachen (Germany), Uppsala University (Sweden) and at Bayer CropScience. During his PhD at Max Planck Institute for Plant Breeding Research, he focused on the evolution of transcriptome responses during immunity in various plant species.